Feng M, et al. – The safety and efficacy of individualized adaptive stereotactic body radiotherapy (SRBT) for liver tumors in patients who had preexisting liver dysfunction, were characterized. Based on a direct biomarker of liver function, the treatment strategy of individualized adaptive therapy had the potential to achieve both high rates of local control and a high degree of safety without sacrificing either. Moreover, individualized adaptive radiotherapy seemed to represent a new treatment paradigm. In this treatment paradigm, the dose was based on individual, rather than population–based, tolerance to treatment.